VRB­PAC unan­i­mous­ly rec­om­mends mono­va­lent, XBB lin­eage for next fal­l's Covid-19 vac­cine cam­paign

The FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee met Thurs­day to as­sess whether the Covid-19 vac­cine needs to be up­dat­ed, with the com­mit­tee vot­ing 21-0 in fa­vor of a new mono­va­lent, XBB lin­eage for shots like­ly com­ing this fall.

Pfiz­er/BioN­Tech, Mod­er­na and No­vavax all pre­sent­ed on what they are like­ly to have ready in the com­ing months, with all three vac­cines po­ten­tial­ly ready as soon as lat­er this sum­mer. Pfiz­er, for in­stance, not­ed that they could have an XBB.1.5 mono­va­lent ver­sion avail­able as soon as the end of next month, or an XBB.1.16 mono­va­lent vac­cine in Au­gust.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA